The European Medicines Agency (EMA) has validated Vertex’s Type II variation application to the Marketing Authorization for Kaftrio (ivacaftor/tezacaftor/elexac 24 November 2023
Almirall has won European Commission (EC) approval for Ebglyss (lebrikizumab) for the treatment of adult and adolescent patients with moderate-to-severe atopic 17 November 2023
On Tuesday, US biotech company Novavax, which is advancing protein-based vaccines with its Matrix-M adjuvant, announced a timely update with its Nuvaxovid XBB.1 1 November 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.